DJIA 17,079.57 -42.44 -0.25%
NASDAQ 4,557.70 -11.93 -0.26%
S&P 500 1,996.74 -3.38 -0.17%
market minute promo

Gilead Sciences (NASDAQ: GILD)

107.51 0.10 (0.09%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GILD $107.51 0.09%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $107.00
Previous Close $107.41
Daily Range $106.74 - $108.11
52-Week Range $58.50 - $108.77
Market Cap $162.5B
P/E Ratio 24.19
Dividend (Yield) $0.00 (0.0%)
Volume 10,297,459
Average Daily Volume 13,655,814
Current FY EPS $7.26

Sector

Healthcare

Industry

Drugs

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary

Has Gilead Sciences, Inc.'s Star Drug Already Peaked?

Prescriptions of Gilead Sciences' hepatitis C drug Sovaldi peaked, but sales will pick up after the new combination product is approved.

Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog

RedHill Expands ERADICATE Study on RHB-105 for H. pylori - Analyst Blog

RedHill Expands ERADICATE Study on RHB-105 for H. pylori - Analyst Blog

Guggenheim S&P 500 Equal Weight ETF Experiences Big Inflow

When Will M&A Come To The Hepatitis C Space?

Bristol-Myers Squibb's Daklinza Threatens Johnson & Johnson More Than Gilead Sciences

European approval of Bristol-Myers Squibb's Daklinza could derail sales of Johnson & Johnson's Olysio, but is unlikely to unseat Gilead's Sovaldi.

Gilead: Let's Make A Deal

Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)

After Reaching All-Time Highs, How Can Gilead Sciences Continue growing?

Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog

See More GILD News...

GILD's Top Competitors

GILD $107.51 (0.09%)
Current stock: GILD
AMGN $138.69 (0.62%)
Current stock: AMGN
CELG $94.70 (-0.04%)
Current stock: CELG
$0.00 (0.00%)
Current stock: